1.62
+0.02(+1.25%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.62 |
| Day High | 1.66 |
| Day Low | 1.59 |
| 52-Week High | 4.01 |
| 52-Week Low | 0.36 |
| Volume | 2.31M |
| Average Volume | 3.29M |
| Market Cap | 264.02M |
| PE | -1.72 |
| EPS | -0.94 |
| Moving Average 50 Days | 1.12 |
| Moving Average 200 Days | 0.9 |
| Change | 0.02 |
If you invested $1000 in Tenaya Therapeutics, Inc. (TNYA) since IPO date, it would be worth $105.54 as of October 04, 2025 at a share price of $1.62. Whereas If you bought $1000 worth of Tenaya Therapeutics, Inc. (TNYA) shares 3 years ago, it would be worth $514.29 as of October 04, 2025 at a share price of $1.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
GlobeNewswire Inc.
Oct 02, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlyi
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 02, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underly
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
GlobeNewswire Inc.
Aug 31, 2025 2:15 PM GMT
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Genotypic Status